With a preclinical model using prostate cancer and mouse melanoma, Fan et al. provided evidence that combining ICOS engagement and CTLA4 blockage could produce synergistic anti-tumor effect [30]. The gene discussed is CTLA4; the disease is Familial prostate cancer.